Stany Zjednoczone - angielski - NLM (National Library of Medicine)

avera mckennan hospital - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

golden state medical supply, inc. - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

avkare - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 10mg - film coated tablet - 10 mg - active: simvastatin 10mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 20mg - film coated tablet - 20 mg - active: simvastatin 20mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 40mg - film coated tablet - 40 mg - active: simvastatin 40mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 5mg - film coated tablet - 5 mg - active: simvastatin 5mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 80mg - film coated tablet - 80 mg - active: simvastatin 80mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate methylated spirits microcrystalline cellulose purified talc purified water   starch titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.